VSBC (VitaSpring Biomedical Co) Cash-to-Debt : 0.07 (As of Oct. 2022)

View and export this data going back to 2019. Start your Free Trial

What is VitaSpring Biomedical Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. VitaSpring Biomedical Co's cash to debt ratio for the quarter that ended in Oct. 2022 was 0.07.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, VitaSpring Biomedical Co couldn't pay off its debt using the cash in hand for the quarter that ended in Oct. 2022.

The historical rank and industry rank for VitaSpring Biomedical Co's Cash-to-Debt or its related term are showing as below:

VSBC's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.695
* Ranked among companies with meaningful Cash-to-Debt only.

VitaSpring Biomedical Co Cash-to-Debt Historical Data

The historical data trend for VitaSpring Biomedical Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

VitaSpring Biomedical Co Cash-to-Debt Chart

VitaSpring Biomedical Co Annual Data

Trend

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Cash-to-Debt

Get a 7-Day Free Trial

0.63

N/A

No Debt

0.23

VitaSpring Biomedical Co Quarterly Data
	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22
Cash-to-Debt	Get a 7-Day Free Trial															0.42	0.23	0.19	0.06	0.07

Competitive Comparison of VitaSpring Biomedical Co's Cash-to-Debt

For the Biotechnology subindustry, VitaSpring Biomedical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VitaSpring Biomedical Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VitaSpring Biomedical Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where VitaSpring Biomedical Co's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

VitaSpring Biomedical Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

VitaSpring Biomedical Co's Cash to Debt Ratio for the fiscal year that ended in Jan. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.107	/	(0	+	0.464)
	=	0.23

VitaSpring Biomedical Co's Cash to Debt Ratio for the quarter that ended in Oct. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.024	/	(0.046	+	0.284)
	=	0.07

VitaSpring Biomedical Co (OTCPK:VSBC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

VitaSpring Biomedical Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of VitaSpring Biomedical Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

VitaSpring Biomedical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VitaSpring Biomedical Co Ltd (OTCPK:VSBC) » Definitions » Cash-to-Debt

Comparable Companies

PTCT HRMY VIR BEAM ROCO:6550 CVAC RLAY SHSE:688520 INSM BOM:539268

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Dr. No. 1620, Irvine, CA, USA, 92618

Website

https://www.vitaspringbio.com

VitaSpring Biomedical Co Ltd is a start-up business company. The company's objective is to develop new drugs in cell medicine. The company also plans to produce X.MSC cytopharmaceuticals.

VitaSpring Biomedical Co Headlines

No Headlines